DAX24.603 -0,7%Est505.970 -0,4%MSCI World4.343 -0,1%Top 10 Crypto9,2300 -7,2%Nas22.767 -2,1%Bitcoin61.380 -4,1%Euro1,1799 -0,2%Öl69,30 +2,2%Gold4.907 -0,8%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
SAP 716460 Novo Nordisk A3EU6F PayPal A14R7U Deutsche Telekom 555750 Rheinmetall 703000 NVIDIA 918422 Siemens Energy ENER6Y Microsoft 870747 Infineon 623100 BASF BASF11 Siemens 723610 DroneShield A2DMAA Bayer BAY001 AMD (Advanced Micro Devices) 863186 Lufthansa 823212
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX letztlich tiefer -- Texas Instruments kauft Silicon Labs in Milliardendeal -- Novo Nordisk: Umsatzrückgang erwartet -- Microsoft, Infineon, Lilly, Uber, Bayer, DroneShield, SAP, PayPal im Fokus
Top News
DroneShield-Aktie nach starkem Vortag im Rückwärtsgang: Ein Warnsignal für Anleger? DroneShield-Aktie nach starkem Vortag im Rückwärtsgang: Ein Warnsignal für Anleger?
ETF-Sparplan kündigen: Schritt-für-Schritt erklärt - Anleitung für Anleger ETF-Sparplan kündigen: Schritt-für-Schritt erklärt - Anleitung für Anleger
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Ampliphi Biosciences Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
6,75 EUR +0,30 EUR +4,65 %
STU
8,00 USD +0,27 USD +3,51 %
BTT
Ampliphi Biosciences jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.238,08 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA2PKLC

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS04216R1023

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolARMP

Ampliphi Biosciences Aktien News

DatumMeistgelesen
PR NewswireArmata Pharmaceuticals Announces Key Opinion Leader Webinar on S. aureus Bacteremia and AP-SA02 Hosted by Jones Research on November 25th at 10:00am EST
finanzen.netAmpliphi Biosciences: Das sind die jüngsten Quartalszahlen
PR NewswireArmata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update
Wer­bungAmpliphi Biosciences-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswireArmata Pharmaceuticals Announces Formal Commissioning of State-of-the-Art cGMP Phage Manufacturing Facility in Los Angeles, California
PR NewswireArmata Pharmaceuticals Highlights Positive Results from Phase 2a diSArm Study of its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, in Late-Breaking Oral Presentation at IDWeek 2025™
PR NewswireArmata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025™
PR NewswireArmata Pharmaceuticals Announces Structural Biology Publication in the Journal of Molecular Biology
PR NewswireArmata Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
finanzen.netAmpliphi Biosciences legte Quartalsergebnis vor
PR NewswireArmata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update
PR NewswireArmata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia
finanzen.netAmpliphi Biosciences präsentierte das Zahlenwerk zum abgelaufenen Jahresviertel
PR NewswireArmata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update
PR NewswireArmata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02
finanzen.netAmpliphi Biosciences gewährte Anlegern Blick in die Bücher
PR NewswireArmata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate Update
PR NewswireArmata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva
PR NewswireArmata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 7th Annual Bacteriophage Therapy Summit
PR NewswireArmata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa...
PR NewswireArmata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting
finanzen.netAmpliphi Biosciences: So schnitt der Konzern im vergangenen Quartal ab
PR NewswireArmata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate Update
PR NewswireArmata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus Bacteremia
PR NewswireArmata Pharmaceuticals Announces Structural Biology Publication
PR NewswireArmata Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
PR NewswireArmata Pharmaceuticals Announces Presentation at the 2024 Military Health System Research Symposium
PR NewswireArmata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial Officer
finanzen.netAmpliphi Biosciences: Quartalsergebnisse zum jüngsten Jahresviertel
PR NewswireArmata Pharmaceuticals Announces Second Quarter 2024 Results and Provides Corporate Update
PR NewswireArmata Pharmaceuticals Receives $5.25 Million of Additional Non-Dilutive Grant Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02
PR NewswireArmata Pharmaceuticals Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa ...
PR NewswireArmata Pharmaceuticals Announces Presentation at Viruses of Microbes 2024
finanzen.netAmpliphi Biosciences: Bilanz zum abgelaufenen Quartal
PR NewswireArmata Pharmaceuticals Announces First Quarter 2024 Results and Provides Corporate Update
finanzen.netAmpliphi Biosciences vermeldete Zahlen zum jüngsten Quartal
PR NewswireArmata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate Update
PR NewswireArmata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva
PR NewswireArmata Pharmaceuticals Announces Presentation at the 6th Annual Bacteriophage Therapy Summit
finanzen.netAmpliphi Biosciences stellte Zahlen zum jüngsten Quartal vor
PR NewswireArmata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate Update

Ampliphi Biosciences News

Ampliphi Biosciences News: auf dieser Seite finden Sie alle Ampliphi Biosciences News und Nachrichten zur Ampliphi Biosciences Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Ampliphi Biosciences News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Ampliphi Biosciences News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.